ruxolitinib cream

Singapore, September 21, 2026 Specialised Therapeutics (ST) has expanded its existing partnership with Incyte to include ruxolitinib cream (Opzelura®)...

WILMINGTON, Del., July 29, 2026 Incyte announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the...

WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...